103 records – page 2 of 6.

Select Title Policy Type Year
EspAddText
EspRemoveText
CMA's Response to Health Canada's Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa's Law) Response to consultation 2015
EspAddText
EspRemoveText
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions. Response to consultation 2016
EspAddText
EspRemoveText
Consultation on the prescription drug list: Naloxone Response to consultation 2016
EspAddText
EspRemoveText
National pharmacare in Canada: Getting there from here Parliamentary submission 2016
EspAddText
EspRemoveText
Health Canada’s Consultation on “Plain and Standardized Packaging” Response to consultation 2016
EspAddText
EspRemoveText
Legalization, regulation and restriction of access to marijuana Response to consultation 2016
EspAddText
EspRemoveText
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada Parliamentary submission 2016
EspAddText
EspRemoveText
Regulation of Self-Care Products in Canada Response to consultation 2016
EspAddText
EspRemoveText
The future of medicine Policy document 2017
EspAddText
EspRemoveText
Corporate privacy policy respecting the collection, use and disclosure of personal information (Update 2012) Policy document 2017
EspAddText
EspRemoveText
Position statement on prescription drug shortages in Canada Policy document 2017
EspAddText
EspRemoveText
Consultation on the renewal of Federal Tobacco Control Strategy Response to consultation 2017
EspAddText
EspRemoveText
CMA submission to the study of Bill C-37 Parliamentary submission 2017
EspAddText
EspRemoveText
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts Parliamentary submission 2017
EspAddText
EspRemoveText
Federal Monitoring and Reporting Regime for MAID Response to consultation 2017
EspAddText
EspRemoveText
Canada’s lower-risk cannabis use guidelines (LRCUG) Policy endorsement 2017
EspAddText
EspRemoveText
Advance care planning Policy document 2017
EspAddText
EspRemoveText
Direct-to-consumer genetic testing Policy document 2017
EspAddText
EspRemoveText
Medical assistance in dying Policy document 2017
EspAddText
EspRemoveText
CMA response to patented medicines regulations consultations Response to consultation 2017

103 records – page 2 of 6.